Search Results
Your search for ,aLl matches 18306 pages
Showing 16951 - 17000Fluorescent Imaging of Lung Lesions During Surgery May Localize Tumors and Improve Precision
More than 80,000 people undergo resection of a pulmonary tumor each year, and currently the only method to determine whether the tumor is malignant is histologic analysis. A new study reported that a targeted molecular contrast agent can be used successfully to render lung adenocarcinomas...
No Difference in Overall Survival With Addition of Quinolone Derivative Vosaroxin to Cytarabine in Relapsed or Refractory AML
In a phase III VALOR trial reported in The Lancet Oncology, Ravandi et al found that the addition of the quinolone derivative vosaroxin to cytarabine did not significantly improve overall survival in patients with relapsed or refractory acute myeloid leukemia (AML). However, differences favoring...
Study Finds Underinvestment in Long-Term Cancer Research
Pharmaceutical firms underinvest in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research, according to a newly published study authored by Massachusetts Institute of Technology (MIT) economists. These findings were published by...
Protein Imbalance in Akt Pathway May Trigger Cancer
Cancer can be caused solely by protein imbalance within cells, a study of ovarian cancer has found. Until now, genetic aberrations have been seen as the main cause of almost all cancer. The research, published by Timsah et al in Oncogene, demonstrates that protein imbalance is a powerful prognostic ...
Intraperitoneal Plus Intravenous Chemotherapy—an Underused Strategy—May Improve Survival in Advanced Ovarian Cancer
An observational study investigating the use and effectiveness of a combination regimen of intraperitoneal and intravenous chemotherapy in the treatment of advanced-stage ovarian cancer has found that although the dual approach substantially improved survival—81% of those treated with the...
Improved Outcomes With Aromatase Inhibitors vs Tamoxifen in Early Breast Cancer
In a patient-level meta-analysis of randomized trials reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 5 years of aromatase inhibitor treatment significantly reduced the recurrence risk vs 5 years of tamoxifen therapy during the first 4 years and...
Race and Institutional Support May Play a Role in Pharmacogenomic Trial Participation
Cancer therapy has evolved to a personalized approach, and important aspects of this method are pharmacogenomic studies that analyze associations between genetic variations and patient drug responses. Moffitt Cancer Center researchers published a study by Dressler et al in the Journal of the...
Modified Mullerian-Inhibiting Substance Suppresses Growth of Some Recurrent Ovarian Tumors in Mouse Model
Use of gene therapy to deliver a protein that suppresses the development of female reproductive organs may improve the survival of patients with ovarian cancer that has recurred after chemotherapy. In a study published by Pepin et al in PNAS Early Edition, a Massachusetts General Hospital (MGH)...
NCIC MA.20 Trial: Addition of Regional Nodal Irradiation in Early Breast Cancer Improves Disease-Free but Not Overall Survival
In a phase III trial (National Cancer Institute of Canada [NCIC] Clinical Trials Group MA.20) reported in The New England Journal of Medicine, Whelan et al found that the addition of regional nodal irradiation to whole-breast irradiation did not improve overall survival in women with node-positive...
Study Finds Exercise in Adolescence Is Linked to Reduced Mortality From Cancer and All Causes in Later Life
A large, population-based prospective cohort study of about 75,000 women has found that adolescent exercise is associated with reduced risk of death due to cancer, cardiovascular disease, and all causes among middle-aged and older women. After adjusting for socioeconomic and lifestyle factors, the...
Omitting Doxorubicin From Postoperative Chemotherapy Has No Significant Survival Effect in Intermediate-Risk Wilms Tumor
In a phase III noninferiority trial (SIOP WT 2001) reported in The Lancet, Pritchard-Jones et al in the SIOP (International Society of Paediatric Oncology) Renal Tumours Study Group found that omission of doxorubicin from postoperative chemotherapy for stage II to III histologic intermediate-risk...
Emergency Department Febrile Neutropenia Pathway for Patients With Cancer Reduces Time to Antibiotic Administration
In a study reported in the Journal of Oncology Practice, Keng et al at Cleveland Clinic found that institution of an emergency department febrile neutropenia pathway for patients with cancer reduced the time to antibiotic administration compared with historical and direct admission cohorts....
FDA Grants Breakthrough Therapy Designation to Lenvatinib for Metastatic Renal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) granted lenvatinib (Lenvima) Breakthrough Therapy designation for investigational use in patients with advanced or metastatic renal cell carcinoma who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy. Lenvatinib...
Researchers Decode Molecular Action of Combination Therapy for Anaplastic Thyroid Cancer
In their bid to find the best combination of therapies to treat anaplastic thyroid cancer, researchers at Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal. In testing multiple HDAC inhibitors in combination with the chemotherapy drug...
FDA Approves Carfilzomib Combination for Patients With Relapsed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved carfilzomib (Kyprolis) in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The approval was based on a demonstration of ...
Reemergence of Racial Disparity in Use of Adjuvant Chemotherapy in Stage III Colon Cancer
In an analysis reported in the Journal of Clinical Oncology, Murphy et al found that disparity in the use of adjuvant chemotherapy in white vs black patients with stage III colon cancer may have recently reemerged after a trend of increasing use in both racial groups. Changes in Use Over...
New Analysis Points the Way to Earlier Diagnosis of Pediatric Chest Tumors
Researchers led by St. Jude Children’s Research Hospital scientists have developed new diagnostic criteria to enable clinicians to distinguish malignant cancerous chest cavity masses from those caused by fungal histoplasmosis infection. Their findings were published by Naeem et al in the...
Study Shows Palliative Chemotherapy in Patients With End-Stage Cancer Did Not Improve Quality of Life and May Be Harmful
Although palliative chemotherapy is used to improve quality of life for patients with end-stage cancer, a study evaluating its use found that palliative chemotherapy did not improve quality of life near death for patients with a moderate or poor performance status and that it worsened quality of...
Low Incidence of Infusion-Related Reactions Reported With 30-Minute Ipilimumab Infusion
In a single-institution study reported in the Journal of Clinical Oncology, Momtaz et al found that the rate of infusion-related reactions remained acceptably low when ipilimumab (Yervoy) 3 mg/kg was infused over 30 minutes in patients with advanced melanoma. The currently approved dose of...
Adding Neoadjuvant mFOLFOX6 After Chemoradiation May Improve Pathologic Complete Response Rate in Locally Advanced Rectal Cancer
In a phase II trial reported in The Lancet Oncology, Garcia-Aguilar et al found that adding neoadjuvant mFOLFOX6 (modified fluorouracil [5-FU], leucovorin, oxaliplatin) after chemoradiation improved the pathologic complete response rate in patients with locally advanced rectal cancer undergoing...
Trial Shows Molecular Subtypes of Diffuse Large B-Cell Lymphoma React Differently to Ibrutinib
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma are more likely to respond to ibrutinib (Imbruvica) than patients with another molecular subtype of the disease. The study was published by Wilson et al in Nature Medicine. In this phase II...
No Progression-Free Survival Benefit of Adding VEGF Inhibitor Cediranib to First-Line Chemotherapy in Advanced Biliary Tract Cancer
In a UK randomized phase II trial (ABC-03) reported in The Lancet Oncology, Valle et al found that adding the VEGF inhibitor cediranib to first-line cisplatin/gemcitabine did not improve progression-free survival in patients with advanced biliary tract cancer. Study Details In the double-blind...
‘Pill on a String’ Could Help Spot Early Signs of Esophageal Cancer
A “pill on a string” developed by researchers at the University of Cambridge could help doctors detect esophageal cancer at an early stage, helping them overcome the problem of wide variation between biopsies, suggests research published by Ross-Innes et al in Nature Genetics. The...
Cancer Diagnosis Among Patients With Diabetes Reduced Adherence to Evidence-Based Diabetes Medications
“A cancer diagnosis among patients with diabetes reduced adherence with evidence-based medications, particularly if patients’ life expectancy was short,” according to a study among Medicare beneficiaries reported in the Journal of Oncology Practice. “These findings emphasize ...
Aggressive Cancer Treatment Near End of Life Persists, Despite Rise in Advance Planning Efforts
In a review of nearly 2,000 surveys with people whose loved ones died of cancer, researchers led by Johns Hopkins School of Medicine experts said they found a 40% increase over a 12-year period in the number of patients with cancer who participated in one form of advance care...
Adverse Event Reporting System Indicates Renal Toxic Effects With BRAF Inhibitors Vemurafenib and Dabrafenib
In an analysis of FDA Adverse Event Reporting System data reported in JAMA Oncology, Jhaveri et al found that the BRAF inhibitors vemurafenib (Zelboraf) and dabrafenib (Tafinlar) were associated with nephrotoxicity. Their findings suggest a need to monitor renal function and electrolyte levels ...
Noninvasive Prenatal Testing May Also Detect Some Maternal Cancers
A study published by Bianchi et al in the Journal of the American Medical Association (JAMA) showed that genetic test results revealed by noninvasive prenatal testing for fetal chromosomal abnormalities may detect underlying conditions in the mother, including cancer. The study reports on a case...
Stereotactic Body Radiotherapy Yields Similar Outcomes in Patients With Biopsy-Proven vs Radiographically Diagnosed Early-Stage NSCLC
In patients with early-stage non–small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy, outcomes were similar between patients with biopsy-proven lesions and those with radiographically diagnosed disease, according to a study by Fischer-Valuck et al in Tumori Journal....
Meta-Analysis Indicates Benefit of Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer With Small Tumors
In a meta-analysis reported in the Journal of Clinical Oncology, O’Sullivan et al found that adjuvant trastuzumab (Herceptin) was associated with a significant disease-free and overall survival benefit among patients with early HER2-positive hormone receptor–positive and hormone...
Extended-Field Intensity-Modulated Radiation Therapy for Cervical and Endometrial Cancers Does Not Increase Risk of Duodenal Toxicity
Women with cervical or endometrial cancer who require treatment to the para-aortic lymph nodes can safely receive extended-field intensity-modulated radiation therapy without increased risk of duodenal toxicity, according to a study by Xu et al in Practical Radiation Oncology. Extended-Field...
Preclinical Studies Demonstrate Activity of Type II JAK2 Inhibitor in B-Cell ALL
Laboratory and animal tests of the type II inhibitor CHZ868, which stabilizes the kinase domain in an inactive conformation, are showing that the compound is highly potent against B-cell acute lymphoblastic leukemias (ALLs) with CRLF2 rearrangements. When combined with dexamethasone, CHZ868 induced ...
Disparities in Use of Breast-Conserving Therapy for Early-Stage Breast Cancer
In a study using National Cancer Data Base data reported in JAMA Surgery, Lautner et al identified several factors associated with the use of breast-conserving therapy in women with early-stage breast cancer, including older age, higher education and income, private insurance, treatment at an...
Diagnosis of Additional Small Breast Cancers Suggests Screening Mammography May Lead to Overdiagnosis
A study of screening mammography across U.S. counties found that “the clearest result of mammography screening is the diagnosis of additional small cancers” but without a “concomitant decline in the detection of larger cancers, which might explain the absence of any significant...
Addition of Bevacizumab to Standard Chemotherapy Does Not Improve Overall Survival in Newly Diagnosed Ovarian Cancer
Final overall survival results of the phase III ICON7 trial reported in The Lancet Oncology by Oza et al indicate no significant increase with the addition of bevacizumab (Avastin) to standard chemotherapy in women with newly diagnosed ovarian cancer. However, overall survival benefit of...
Early Study Suggests Which Glioblastoma Patients May Benefit From Dasatinib
Clinicians testing the drug dasatinib (Sprycel), approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical...
DNA Shed From Head and Neck Tumors Detected in Blood and Saliva
On the hunt for better cancer screening tests, Johns Hopkins scientists led a proof-of-principle study that successfully identified tumor DNA shed in the blood and saliva of 93 patients with head and neck cancer. A report on the findings was published by Wang et al in Science Translational...
Breastfeeding Associated With Reduced Risk of Breast Cancer Recurrence and Mortality in Luminal A Subtype
In a study reported in the Journal of the National Cancer Institute, Kwan et al found that women with basal-like tumors were less likely to have breastfed than those with luminal A tumors and that breastfeeding was associated with a significantly reduced risk of recurrence and breast...
Pembrolizumab Increases Progression-Free Survival vs Chemotherapy in Ipilimumab-Refractory Advanced Melanoma
In the randomized phase II KEYNOTE-002 trial reported in The Lancet Oncology, Ribas et al found that treatment with the anti–PD-1 antibody pembrolizumab (Keytruda) prolonged progression-free survival vs investigator-choice chemotherapy in patients with advanced melanoma progressing on...
Study Finds More Selective Ordering of Breast Biomarker Tests Could Save Millions in Health-Care Dollars
A review of medical records for almost 200 patients with breast cancer suggests that more selective use of biomarker testing for such patients has the potential to save millions of dollars in health-care spending without compromising care, according to Johns Hopkins researchers. Specifically,...
ASCO Endorses ASTRO Guideline on Radiation Therapy After Surgery for Endometrial Cancer
The American Society of Clinical Oncology (ASCO) issued an endorsement of the American Society for Radiation Oncology (ASTRO) clinical practice guideline on postoperative radiation therapy for women with endometrial (uterine) cancer. The endorsement was published by Meyer et al in the Journal of...
Community-Based Trial Suggests No Benefit of Adding Thalidomide or Melphalan to Bortezomib-Based First-Line Treatment of Myeloma
In the U.S. community-based phase IIIB UPFRONT trial reported in the Journal of Clinical Oncology, Niesvizky et al found no benefit of adding thalidomide (Thalomid) or melphalan to first-line bortezomib (Velcade)-based treatment in transplant-ineligible myeloma patients. Study Details In the...
Daratumumab Expanded Access Program Open to Eligible U.S. Patients With Heavily Pretreated Multiple Myeloma
Janssen Biotech, Inc, announced the opening of a daratumumab expanded access program for eligible U.S. patients. Daratumumab is an investigational human anti-CD38 monoclonal antibody being evaluated in clinical trials as a treatment for patients with multiple myeloma. The multicenter, open-label...
Study Identifies Geographic Hot Spots With the Highest Colorectal Cancer Death Rates
Gains have been made in the overall reduction in the death rates of colorectal cancer in the United States. A new study by Siegel et al has identified three distinct geographic hot spots where colorectal cancer death rates remain elevated over other parts of the country. These hot spots were found...
Risk Factors for Interval Invasive Second Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Lee et al found that factors associated with an increased risk of interval second breast cancers after negative surveillance mammography included grade II primary breast cancer, lumpectomy without radiation, interval primary...
ESMO World GI 2015: Second-Line Cetuximab Active Beyond Progression in Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer that are free of mutations in the KRAS, NRAS, BRAF, and PIK3CA genes showed a significant benefit from continuing antiepidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody. ...
ESMO World GI 2015: Studies Confirm Regorafenib Benefit in Pretreated Metastatic Colorectal Cancer
The phase IIIb CONSIGN trial has confirmed the benefit of regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer, researchers announced July 3 at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer in Barcelona, Spain (Abstract...
Chinese Study Finds Serum MicroRNA Classifier Better Than Alpha-Fetoprotein for Early Detection of Hepatocellular Carcinoma
In a study reported in The Lancet Oncology, Lin et al developed a serum microRNA classifier that was more accurate than alpha-fetoprotein in detecting preclinical hepatocellular carcinoma. Study Details The study involved healthy controls, inactive hepatitis B surface antigen carriers,...
Survival Benefit of Surgery Lower for Low-Grade vs Higher-Grade Ductal Carcinoma in Situ
In a population-based cohort study reported in JAMA Surgery, Sagara et al found that the breast cancer–specific survival benefit associated with surgery for low-grade ductal carcinoma in situ is lower than that associated with surgery for intermediate- or high-grade ductal carcinoma in situ. ...
ESMO World GI 2015: SENRI Trial Evaluates NK1 Antagonists for Emesis Prevention in Oxaliplatin-Based Chemotherapy
The SENRI trial has opened the window to evaluate neurokinin 1 (NK1) antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, said European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO) spokesperson and antiemetics expert Fausto Roila, MD....
ESMO World GI 2015: Low Body Mass Index Associated With Poorer Survival in Metastatic Colorectal Cancer
Although being overweight with a high body mass index (BMI) has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well as previously expected after treatment for advanced cancer, according to a new study from Duke Medicine. The study, which was...
